Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies by M.F. George et al.
Multiple sclerosis risk loci and disease
severity in 7,125 individuals from
10 studies
ABSTRACT
Objective: We investigated the association between 52 risk variants identified through genome-
wide association studies and disease severity in multiple sclerosis (MS).
Methods: Ten unique MS case data sets were analyzed. The Multiple Sclerosis Severity Score
(MSSS) was calculated using the Expanded Disability Status Scale at study entry and disease
duration. MSSS was considered as a continuous variable and as 2 dichotomous variables (median
and extreme ends; MSSS of #5 vs .5 and MSSS of ,2.5 vs $7.5, respectively). Single
nucleotide polymorphisms (SNPs) were examined individually and as both combined weighted
genetic risk score (wGRS) and unweighted genetic risk score (GRS) for association with disease
severity. Random-effects meta-analyses were conducted and adjusted for cohort, sex, age at
onset, and HLA-DRB1*15:01.
Results: A total of 7,125MScaseswere analyzed. ThewGRSandGRSwere not strongly associated
with disease severity after accounting for cohort, sex, age at onset, and HLA-DRB1*15:01. After
restricting analyses to cases with disease duration $10 years, associations were null (p value
$0.05). No SNP was associated with disease severity after adjusting for multiple testing.
Conclusions: The largest meta-analysis of establishedMS genetic risk variants and disease severity,
to date, was performed. Results suggest that the investigatedMS genetic risk variants are not asso-
ciatedwithMSSS, even after controlling for potential confounders. Further research in large cohorts
is needed to identify genetic determinants of disease severity using sensitive clinical and MRI meas-
ures, which are critical to understanding disease mechanisms and guiding development of effective
treatments. Neurol Genet 2016;2:e87; doi: 10.1212/NXG.0000000000000087
GLOSSARY
CI 5 confidence interval; EAE 5 experimental autoimmune encephalomyelitis; EDSS 5 Expanded Disability Severity Scale;
GRS5 unweighted genetic risk score; GWAS5 genome-wide association studies; KPNC5 Kaiser Permanente Medical Care
Plan in the Northern California Region; MHC 5 major histocompatibility complex; MS 5 multiple sclerosis; MSSS 5Multiple
Sclerosis Severity Score; OR 5 odds ratio; SNP 5 single nucleotide polymorphism; UCSF 5 University of California at San
Francisco; wGRS 5 weighted genetic risk score.
Multiple sclerosis (MS) is a severe autoimmune inflammatory disease of the central nervous sys-
tem. Neurologic damage in MS is caused by irreversible demyelination of axons and lesion for-
mation. Although early disease may manifest as attacks with full recovery, over time MS is
extremely debilitating for the majority of patients. Only 37% of individuals with mild MS
are employed, and within 15 years of diagnosis, 50%–60% of patients will require assistance
with walking, posing tremendous economic and societal burden.1,2
Evidence suggests that both genetic and environmental components contribute to the risk of
MS. The strongest genetic risk factor is within the human leukocyte antigen (HLA)-DRB1 locus,
specifically the 15:01 allele,3 and studies support the presence of additional independent sus-
ceptibility alleles within the major histocompatibility complex (MHC) Class I and Class II
regions.4 However, these genes have not been convincingly associated with progression.3,5
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Environmental risk factors for MS include
infection with Epstein-Barr virus, tobacco
smoke exposure, low serum levels of vitamin
D, and childhood/adolescent obesity.6,7 With
the exception of tobacco smoke and low vita-
min D,8,9 environmental influences on MS
disease severity are unknown.
Through international collaboration,
genome-wide association studies (GWAS) fol-
lowed by replication have identified a large num-
ber of non-MHC MS risk variants.10,11 We
hypothesized that MS risk variants might also
influence disease severity. We investigated the
association of the Multiple Sclerosis Severity
Score (MSSS) with both a weighted genetic risk
score (wGRS) and unweighted genetic risk score
(GRS) comprising 52 established risk variant
alleles, and each susceptibility variant alone in
7,125 MS cases from 10 independent cohorts.
METHODS Study populations. Ten independent and well-
characterized MS case data sets were analyzed (table 1). The
analysis included 1,079 white non-Hispanic MS patients
recruited from Kaiser Permanente Medical Care Plan in the
Northern California Region (KPNC).12 The following
additional cases were included: 1,019 MS white non-Hispanic
patients recruited from 2 other clinical sites in the United States
(US1 and US2)5; 422 MS patients recruited through
a population-based study in Oslo, Norway (Norway)13; 2,348
MS patients recruited through a population-based study in
Sweden (Sweden)14; 890 MS patients from a cohort in
Denmark (Denmark)11; 485 white non-Hispanic MS patients
from a University of California San Francisco (UCSF)15
cohort; 678 MS patients from 2 cohorts recruited in Italy
(Italy1 and Italy2)10,16; and 204 patients from a Tasmanian
cohort study (Australia).17,18 Each case included in the meta-
analysis fulfilled disease criteria for MS.19 Classical HLA-
DRB1*15:01 typing was used in the KPNC, Sweden, and
UCSF studies. Validated tagging single nucleotide
polymorphisms (SNPs) for DRB1*15:01 were used in the US1
and US2, Italy1 and Italy2, and Australia (rs9271366), Norway
(rs9270986), and Denmark (rs3135388) studies. Each of these
tagging SNPs was tested against the classical high-resolution
HLA-DRB1 typing performed in the KPNC data set; the
correlations (r2) were 0.99, 0.91, and 0.95, respectively.
Standard protocol approvals, registrations, and patient
consents. Each study protocol was approved by the appropriate
Institutional Review Board of the participating academic institu-
tion. All participants provided written informed consent.
Table 1 Characteristics of non-Hispanic white MS cases in 10 cohorts
Mean (SD)/frequency (%)
KPNC US Norway Sweden Denmark UCSF Italy Australia Meta-analysis
No. of cases 1,079 1,019 422 2,348 890 485 678 204 7,125
MSSS continuous 3.37 (2.6) 3.28 (2.6) 4.59 (3.0) 4.61 (2.8) 4.48 (2.6) 2.98 (2.4) 4.57 (2.9) 4.12 (2.7) 4.09 (2.8)
MSSS binary (high) 255 (23.6) 261 (25.6) 180 (42.7) 1,045 (44.5) 370 (41.6) 101 (20.8) 295 (43.5) 73 (35.8) 2,580 (36.2)
MSSS extreme
(high)
129 (19.6) 103 (17.3) 101 (40.2) 474 (41.2) 136 (36.8) 31 (10.5) 150 (40.7) 30 (28.6) 1,154 (30.4)
Female 868 (80.4) 779 (76.5) 309 (73.2) 1,702 (72.5) 614 (69.0) 333 (68.7) 436 (64.3) 147 (72.1) 5,188 (72.8)
Age at onset 31.94 (9.8) 31.03 (8.5) 32.66 (9.4) 34.60 (10.7) 30.92 (8.9) 33.47 (9.3) 32.50 (10.5) 35.25 (10.2) 32.85 (10.0)
HLA-DRB1*15:01
(positive)
581 (53.9) 567 (55.6) 243 (57.6) 1,366 (58.2) 534 (60.0) 224 (46.2) 189 (27.9) 120 (58.8) 3,824 (53.7)
Disease duration 12.23 (8.5) 12.05 (8.5) 16.16 (10.5) 9.71 (8.6) 12.23 (7.8) 9.54 (9.1) 11.38 (8.5) 15.67 (10.2) 11.44 (8.9)
wGRS 6.75 (0.5) 6.59 (0.5) 6.84 (0.5) 6.74 (0.5) 6.68 (0.5) 6.71 (0.5) 6.85 (0.5) 6.72 (0.5) 6.73 (0.5)
GRS 56.72 (4.4) 55.77 (4.4) 57.11 (4.4) 56.44 (4.5) 56.38 (4.5) 56.46 (4.3) 57.81 (4.5) 56.47 (4.6) 56.55 (4.5)
Genotyping
platform
Affymetrix
GeneChip
Human Mapping
500K Array set
Affymetrix
GeneChip
Human Mapping
500K Array set
TaqMan
OpenArray
Genotyping
Technology
Immunochip—
Illumina Infinium
HD Custom
Array and
Illumina Human
Quad 660
Immunochip—
Illumina
Infinium HD
Custom Array
Illumina
HumanHap550
Beadchip circa
2006
Illumina
Human Quad
660
Illumina
Infinium
Hap370CNV
array
—
Abbreviations: GRS 5 unweighted genetic risk score; KPNC 5 Kaiser Permanente Medical Care Plan in the Northern California Region; MS 5 multiple
sclerosis; MSSS 5 Multiple Sclerosis Severity Score; SNP 5 single nucleotide polymorphism; UCSF 5 University of California at San Francisco; wGRS 5
weighted genetic risk score.
MSSS is presented as a continuous variable and as 2 dichotomous variables. The first dichotomous variable was based on the median MSSS value, defined
as MSSS #5 vs .5, with a smaller score indicating a more benign phenotype. The second dichotomous variable was based on extreme ends of the MSSS
distribution, defined as MSSS,2.5 vs$7.5. HLA-DRB1*15:01 tag SNP if classical HLA typing was not available: US and Italy cohorts used rs9271366 as
a tag SNP, Norway used rs9270986 as a tag SNP, and Denmark used rs3135388 as a tag SNP. All cohorts had data for all 52 individual SNPs, except the
US and Australian cohorts. The US cohort used the following SNPs as tagging SNPs: rs6685440 tags rs11581062; and rs8106574 tags rs1077667.
The Australian cohort imputed the following SNPs: rs1323292, rs7522462, rs17174870, rs10201872, rs669607, rs12212193, rs17066096,
rs13192841, rs354033, rs1520333, rs10466829, rs2119704, rs7200786, rs13333054, and rs2425752. The US cohort contains 2 cohorts—
US1 and US2. The Italy cohort contains 2 cohorts—Italy1 and Italy2. They are combined in table 1, but analyzed separately in the meta-analysis.
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Genotyping and imputation. In addition to HLA-
DRB1*15:01 (described above), a group of 52 independent
non-MHC GWAS SNPs were chosen for the present study.
They were selected because they were previously identified and
further replicated through GWAS, and they demonstrated larger
magnitudes of effect on disease risk. All participants were
genotyped using separate platforms: Affymetrix platform using
the GeneChip Human Mapping 500K Array set (KPNC and
United States), TaqMan OpenArray Genotyping Technology
(Norway), Illumina Infinium HD Custom Array and Illumina
Human Quad 660 (Sweden, Denmark, and Italy), and Illumina
HumanHap550 Beadchip ©2006 (UCSF). All cohorts, except
United States and Australia, contained genotyping information
for all 52 variants. In the United States, tagging SNPs were used
as proxies for 2 missing candidate SNPs: rs6693456 tagged
rs11581062 (r2 5 0.95), and rs8106574 tagged rs1077667
(r2 5 0.63), based on publicly available data. In the Australia
data set, 15 SNPs were missing: rs1323292, rs7522462,
rs17174870, rs10201872, rs669607, rs12212193, rs17066096,
rs13192841, rs354033, rs1520333, rs10466829, rs2119704,
rs7200786, rs13333054, and rs2425752. Genetic data within
1-MB regions around all missing SNPs were available for
each patient; therefore, imputation was possible against the
1000 Genomes reference. After imputation, missingness was
lower than 2% in all cohorts. However, to recover all missing
genotypes, the risk allele frequency from each cohort was
used to estimate the missing genotypes. The estimation for
each individual was made using a multinomial distribution
generated from 1,000 random samples from each respective
cohort. The probability for each of the 3 possible genotypes
was generated. When a single genotype was missing for an
individual, one sample was drawn randomly from the
generated distribution from that cohort. This was done for
a total of 146 individuals (KPNC 5 92, Norway 5 19,
Sweden 5 22, Denmark 5 9, UCSF 5 15, and Italy 5 8)
and a total of 48 SNPs (KPNC 5 44, Norway 5 15,
Sweden 5 4, Denmark 5 2, UCSF 5 10, and Italy 5 8).
Weighted and unweighted genetic risk scores. wGRS was
calculated for each MS patient using the discovery odds ratios
(ORs) as the weight for each of 52 non-MHC risk alleles
derived from 9,772 MS cases and 17,376 controls,10 as
previously described. In brief, the number of risk alleles for
each SNP was multiplied by the weight for that variant, and
then the sum across all 52 variants was calculated (table 1).10,20
GRS was calculated as the sum of risk allele copies for each SNP
without weighting (table 1). Both wGRS and GRS were analyzed
as continuous variables.
Multiple Sclerosis Severity Score. MSSS is a probabilistic
algorithm that uses the Expanded Disability Severity Scale
(EDSS) to calculate disease severity and duration of disease,
which was defined as time between first symptom and EDSS
assessment.21 The MSSS for each patient in the current study
was assigned using Global MSSS reference data derived from
a large independent cohort of 9,892 patients with EDSS and
disease duration ranging from 1 to .30 years. EDSS scores from
a pooled reference patient cohort were ranked as previously
described,21 and the average of the lowest and highest ranks for
each possible EDSS value was calculated, taking into account also,
scores reported for 2 years before and after each designated time
point. These averages were normalized to account for the number
of available assessments for each year (disease duration) and mul-
tiplied by 10. MSSS was analyzed as a continuous variable and as
2 dichotomous variables, as previously described.5 In brief,
a binary MSSS variable was based on the median MSSS value,
defined as MSSS#5 vs.5, with a smaller score indicating more
benign or “mild” disease. The second variable was based on
extreme ends of the MSSS distribution, defined as MSSS ,2.5
(benign) vs $7.5 (severe) (table 1, figure 1).
Statistical analysis. All 10 data sets were included in a random-
effects meta-analysis. Random-effects meta-analysis allows for
heterogeneity across studies because of inherent differences
and/or differential biases among each cohort, unlike fixed-
effects models, which assume a single common effect underlies
each study. A random-effects meta-analysis is generally more
conservative, generating wider confidence intervals (CIs) and
larger p values. Weighted and unweighted GRS, and all 52
non-MHC risk variants, were tested with the 3 MSSS
outcomes in the meta-analysis.
In addition, analyses restricted to cases with a preestablished
disease duration greater than or equal to 10 years were conducted
to increase the likelihood that the MSSS measurement was stable.
Both adjusted linear and logistic regression models were used to
estimate adjusted beta values (b), ORs, and 95% CIs. The
meta-analysis was adjusted for sex, age at onset, and HLA-
DRB1*15:01. All analyses were conducted in STATA v13.1 (Sta-
taCorp, College Station, TX). The present study had sufficient
power for all analyses (table e-1 at Neurology.org/ng).
RESULTS A total of 7,125 individuals were included
in the meta-analysis of the 3 MSSS outcomes (table 1).
The overall distributions of MSSS demonstrated
similarities across individual cohorts (figure 1) and
were comparable to those in other cohorts reported
previously21; however, there were some notable
Figure 1 Density plot of MSSS by cohort
The density plot represents the frequency distribution of MSSS in each of the 10 cohorts
and the total 7,125 individuals with MS. KPNC 5 Kaiser Permanente Medical Care Plan in
the Northern California Region; MS5multiple sclerosis; MSSS5Multiple Sclerosis Severity
Score. UCSF 5 University of California at San Francisco.
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differences. Cohorts from Nordic countries and Italy
had a larger proportion of cases with greater disease
severity; disease duration, on average, was shorter in
the Swedish and US (UCSF) cohorts (table 1). The
sex distribution was also very similar across cohorts,
with a 3:1 female to male ratio; KPNC had the
highest proportion of females (80.4%), and Italy had
the lowest proportion of females (64.3%) (table 1). Age
at onset was similar among all cohorts and normally
distributed, ranging from 30.9 years of age in Denmark
to 35.3 years of age in Australia (table 1, figure 2). On
average, disease duration since first symptom was 11.4
years across all cohorts and normally distributed,
ranging from 9.5 years in UCSF to 16.2 years in
Norway (table 1, figure e-1). Last, the distribution of
HLA-DRB1*15:01 was typical of established genetic
patterns in the literature (table 1): MS participants of
Northern European descent were more likely to be
HLA-DRB1*15:01 positive than participants in the
Italy cohort.22 The non-MHC wGRS and GRS were
similar across cohorts (figures e-2 and e-3).
Meta-analyses accounting for the random effect of
each cohort were used. We observed some evidence
for association with wGRS and GRS for the MSSS
outcomes (table 2). However, after restricting the
data set to individuals who had a disease duration
of 10 years or more, no significant associations
remained (table e-2). Sex, age at onset, and
HLA-DRB1*15:01 status were all analyzed as fixed
effects. Sex and age at onset were consistently associ-
ated with MSSS in all 3 models, even after restricting
to individuals with 10 years or more of disease (all p
values ,0.001) (table 2 and table e-2). Male sex and
a later age at onset were both associated with more
severe disease. HLA-DRB1*15:01 was not associated
with MSSS in any of the models.
The 52 non-MHC risk variants were also tested
individually in random-effects meta-analytic models
adjusting for sex, age at onset, andHLA-DRB1*15:01
across all MS cases (full cohort), and in MS cases with
disease duration of 10 years or more (restricted
cohort) (table 3, table e-3). In the full cohort, 2 var-
iants showed evidence of association for all 3 MSSS
outcomes: rs874628 and rs650258, within MPV17L2
and 44-kb upstream of CD6, respectively. Similar re-
sults were observed in the restricted cohort (data not
shown). All associations were in the same direction as
the wGRS and GRS. However, after accounting
for multiple testing, no single variant remained
significant. When analyses were stratified by
DRB1*15:01-positive and -negative carrier status in
cases, results were similar (data not shown). We also
restricted the above analyses to combined US, Euro-
pean, and Australian cohorts separately and did not
observe any cohort-specific associations betweenMSSS
and the wGRS or GRS (data not shown).
DISCUSSION The identification of disease-
modifying genes in MS is critical to further our
understanding of disease pathogenesis, given the
phenotype heterogeneity observed in patients for
clinical manifestations, temporal course, and disease
severity. This important topic has been previously
reviewed, and several challenges have been
described.23 Minimal progress has been made in the
past decade owing mostly to the need for large, well-
designed studies to detect presumably modest genetic
effects, similar to what has been observed for GWAS,
and clinical outcome data for large numbers of
patients that accurately capture measures likely to
be modified by genetic variation. Here, a meta-
analysis of association between 52 established non-
MHC MS genetic risk factors with larger effect sizes
demonstrated in GWAS and disease severity was
performed. Thus far, this is the largest combined
MS patient cohort used to evaluate the relationship
between established risk variants and disease severity.
Ten independent and well-characterized data sets
comprising 7,125 individuals with clinically definite
MS were studied. The hypothesis that one or more
known MS genetic risk variants are also associated
with disease severity characterized by MSSS was
comprehensively tested. Genetic factors that
Figure 2 Density plot of age at onset by cohort
The density plot represents the frequency distribution of age at onset in each of the 10
cohorts and the total 7,125 individuals with MS. KPNC 5 Kaiser Permanente Medical Care
Plan in the Northern California Region; MS 5 multiple sclerosis; MSSS 5 Multiple Sclerosis
Severity Score. UCSF 5 University of California at San Francisco.
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influence disease susceptibility tested here were not
shown convincingly to affect disease severity.
The individuals included in this analysis are repre-
sentative of the international MS population with re-
gard to sex distribution, average age at onset, and
proportion of HLA-DRB1*15:01 allele carriers. Male
sex and older age at onset were associated with more
severe disease, which is consistent with other re-
ports.24 While HLA-DRB1*15:01 is an established
risk factor for MS, it was not associated with MS
disease severity here, as in previous studies that exam-
ined MSSS3,5 and brain atrophy.25
Available MS family data show that familial factors
do not substantially influence eventual disease sever-
ity. However, they may increase the probability of
a progressive clinical course, either from onset or after
a phase of relapsing remitting disease, and evidence
suggests that genetic influences are involved.26 Find-
ings from studies of other neurodegenerative diseases,
such as Alzheimer disease and Parkinson disease, have
linked disease progression with specific genetic
markers, also raising the possibility that MS progres-
sion might have a genetic component,27,28 given evi-
dence for both neurodegeneration and inflammation
in MS. However, to date, there has been limited
success identifying non-MHC genetic associations
with disease severity or other clinical phenotypes in
MS. One study showed that a small subset (n 5 16)
of risk variants investigated in the present study was
not associated with clinical and MRI outcomes in 179
recently diagnosed MS patients.29 However, the
cumulative burden of non-MHC risk variants (n 5
110) contributed modestly to the number of relapses
in 842 MS patients.30 Furthermore, some variants
studied (n5 17) were associated with attack severity,
recovery, or frequency in 503 recently diagnosed MS
cases.31 Relapse data were not available for the present
study. These observations require further investiga-
tion and much larger samples sizes for confirmation.
The most compelling evidence for genetic associa-
tions with cerebrospinal fluid antibody levels, both
immunoglobulin G index and oligoclonal band pos-
itive status, was reported recently for MHC and
immunoglobulin heavy-chain region genes in 6,950
patients.32 Both antibodies are markers of more severe
disease in MS. The results, in conjunction with the
present study findings, underscore the need for new
studies to identify or exclude genetic contributions to
disease severity in MS.
There is evidence in animal models related to MS
to suggest that risk alleles have an effect on progres-
sion. The experimental autoimmune encephalomyeli-
tis (EAE) model, which mirrors an inflammatory
autoimmune disease of the central nervous system
in rats and mice, has offered numerous experimental
insights into MS. When genetically dissected into
high-resolution quantitative trait loci, Eae25 and
Eae29 have been shown to influence both suscepti-
bility and progression.33,34 In addition, differential
expression of an interleukin 2 (IL2) repressor in the
gene ZEB1 results in EAE severity changes.35 Simi-
larly, congenic rats with Eae18b locus have been
Table 2 Meta-analysis results for wGRS and GRS and MSSS in 7,125 MS cases
MSSS outcome
Continuous Binary Extremea
b (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
wGRS (unadjusted) 0.08 (20.1 to 0.2) 0.22 1.1 (1.0–1.2) 0.36 1.1 (1.0–1.3) 0.17
wGRS (adjusted) 0.1 (0.01 to 0.3) 0.03 1.1 (1.0–1.2) 0.09 1.2 (1.0–1.4) 0.02
Sex 20.6 (20.7 to 20.4) ,0.001 0.7 (0.6–0.8) ,0.001 0.5 (0.5–0.6) ,0.001
Age at onset 0.06 (0.05 to 0.07) ,0.001 1.0 (1.0–1.0) ,0.001 1.1 (1.1–1.1) ,0.001
HLA-DRB1*15:01 20.02 (20.1 to 0.1) 0.76 1.0 (0.9–1.1) 0.65 1.0 (0.8–1.1) 0.75
GRS (unadjusted) 0.01 (20.004 to 0.02) 0.18 1.0 (1.0–1.0) 0.32 1.0 (1.0–1.0) 0.11
GRS (adjusted) 0.02 (0.002 to 0.03) 0.03 1.0 (1.0–1.0) 0.09 1.0 (1.0–1.0) 0.01
Sex 20.6 (20.7 to 20.4) ,0.001 0.7 (0.6–0.8) ,0.001 0.5 (0.5–0.6) ,0.001
Age at onset 0.06 (0.05 to 0.07) ,0.001 1.0 (1.0–1.0) ,0.001 1.1 (1.1–1.1) ,0.001
HLA-DRB1*15:01 20.02 (20.1 to 0.1) 0.77 1.0 (0.9–1.1) 0.66 1.0 (0.8–1.1) 0.76
Abbreviations: CI 5 confidence interval; GRS 5 unweighted genetic risk score; MS 5 multiple sclerosis; MSSS 5 Multiple
Sclerosis Severity Score; OR 5 odds ratio; wGRS 5 weighted genetic risk score.
All bs and ORs are from the random-effects models. Unadjusted and adjusted results are shown. Adjusted models included
the following covariates: sex, age at onset, and HLA-DRB1*15:01. All bs and ORs for the covariates in the adjusted models
are also listed above.
aA total of 3,795 individuals with MS are included in this analysis.
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Table 3 Meta-analysis results for 52 SNPs and MSSS in 7,125 MS cases
Chr Gene SNP
MSSS outcome
Continuous Binary Extremea
b (95% CI)b p Value OR (95% CI)b p Value OR (95% CI)b p Value
1 MMEL1 rs4648356 20.07 (20.2 to 0.02) 0.14 1.0 (0.9–1.1) 0.45 0.9 (0.8–1.0) 0.14
EVI5 rs11810217 0.06 (20.03 to 0.2) 0.21 1.1 (1.0–1.1) 0.27 1.1 (1.0–1.2) 0.15
VCAM1 rs11581062 0.05 (20.05 to 0.1) 0.32 1.0 (1.0–1.1) 0.24 1.0 (0.9–1.2) 0.65
CD58 rs1335532 0.07 (20.07 to 0.2) 0.32 1.1 (0.9–1.2) 0.44 1.1 (0.9–1.3) 0.35
RGS1 rs1323292 20.1 (20.2 to 0.01) 0.06 0.9 (0.8–1.0) 0.01 1.0 (0.8–1.1) 0.48
C1orf106 rs7522462 20.09 (20.2 to 0.01) 0.09 0.9 (0.9–1.0) 0.08 0.9 (0.8–1.0) 0.08
2 No gene rs12466022 0.05 (20.05 to 0.2) 0.34 1.0 (1.0–1.1) 0.49 1.0 (0.9–1.2) 0.54
PLEK rs7595037 0.05 (20.03 to 0.1) 0.23 1.0 (1.0–1.1) 0.55 1.1 (1.0–1.2) 0.16
MERTK rs17174870 20.003 (20.1 to 0.10) 0.94 1.0 (0.9–1.1) 0.71 1.0 (0.9–1.2) 0.80
3 SP140 rs10201872 0.01 (20.1 to 0.1) 0.82 1.0 (0.9–1.1) 0.69 1.0 (0.9–1.2) 0.99
EOMES rs11129295 0.02 (20.07 to 0.1) 0.64 1.0 (0.9–1.1) 0.98 1.0 (0.9–1.1) 0.93
No gene rs669607 0.09 (20.003 to 0.2) 0.05 1.1 (0.9–1.1) 0.12 1.1 (1.0–1.2) 0.08
CBLB rs2028597 0.06 (20.1 to 0.2) 0.49 1.0 (0.9–1.2) 0.68 1.0 (0.8–1.2) 0.88
TMEM39A rs2293370 20.1 (20.2 to 0.02) 0.09 0.9 (0.8–1.0) 0.07 0.9 (0.8–1.1) 0.18
CD86 rs9282641 20.05 (20.2 to 0.1) 0.56 1.0 (0.9–1.1) 0.69 1.0 (0.8–1.2) 0.76
IL12A rs2243123 0.01 (20.08 to 0.1) 0.82 1.0 (0.9–1.1) 0.69 1.0 (0.9–1.1) 0.91
5 IL7R rs6897932 0.004 (20.1 to 0.1) 0.93 1.0 (0.9–1.1) 0.61 1.0 (0.9–1.1) 0.76
PTGER4 rs4613763 0.06 (20.06 to 0.2) 0.31 1.1 (1.0–1.2) 0.08 1.1 (1.0–1.3) 0.15
IL12B rs2546890 0.05 (20.03 to 0.1) 0.24 1.0 (0.9–1.1) 0.90 1.1 (1.0–1.2) 0.06
6 BACH2 rs12212193 0.03 (20.06 to 0.1) 0.56 1.0 (0.9–1.1) 0.80 1.0 (0.9–1.2) 0.58
THEMIS rs802734 0.03 (20.07 to 0.1) 0.58 1.0 (0.9–1.1) 0.67 1.1 (0.9–1.2) 0.40
MYB rs11154801 0.08 (20.01 to 0.2) 0.08 1.1 (1.0–1.2) 0.10 1.1 (1.0–1.2) 0.15
IL22RA2 rs17066096 0.09 (20.01 to 0.2) 0.09 1.1 (1.0–1.2) 0.14 1.2 (1.0–1.3) 0.01
No gene rs13192841 20.02 (20.1 to 0.08) 0.71 1.0 (0.9–1.1) 0.77 1.0 (0.9–1.1) 0.52
TAGAP rs1738074 20.03 (20.1 to 0.06) 0.50 1.0 (0.9–1.1) 0.87 1.0 (0.9–1.1) 0.54
7 ZNF746 rs354033 20.03 (20.1 to 0.07) 0.56 1.0 (0.9–1.1) 0.86 0.9 (0.8–1.1) 0.31
8 IL7 rs1520333 20.01 (20.1 to 0.09) 0.89 1.0 (1.0–1.1) 0.30 1.0 (0.9–1.1) 0.72
MYC rs4410871 0.06 (20.04 to 0.2) 0.25 1.1 (1.0–1.1) 0.28 1.0 (0.9–1.2) 0.54
PVT1 rs2019960 0.05 (20.05 to 0.2) 0.32 1.0 (1.0–1.1) 0.49 1.1 (0.9–1.2) 0.38
10 IL2RA rs3118470 0.05 (20.04 to 0.1) 0.30 1.0 (0.9–1.1) 0.62 1.1 (1.0–1.2) 0.07
ZMIZ1 rs1250550 0.04 (20.05 to 0.1) 0.37 1.1 (1.0–1.1) 0.24 1.1 (1.0–1.2) 0.14
HHEX rs7923837 0.02 (20.07 to 0.1) 0.69 1.0 (1.0–1.1) 0.56 1.0 (0.9–1.1) 0.80
11 CD6 rs650258 0.1 (0.02 to 0.2) 0.02 1.1 (1.0–1.2) 0.02 1.2 (1.0–1.3) 0.01
12 TNFRSF1A rs1800693 20.02 (20.1 to 0.1) 0.63 1.0 (0.9–1.1) 0.78 1.0 (0.9–1.1) 0.60
CLECL1 rs10466829 0.02 (20.06 to 0.1) 0.61 1.0 (0.9–1.1) 0.84 1.1 (1.0–1.2) 0.23
CYP27B1 rs12368653 20.04 (20.1 to 0.05) 0.42 1.0 (0.9–1.1) 0.61 1.0 (0.9–1.1) 0.43
ARL61P4 rs949143 0.07 (20.03 to 0.2) 0.16 1.0 (1.0–1.1) 0.55 1.1 (1.0–1.2) 0.16
14 ZFP36L1 rs4902647 0.06 (20.03 to 0.1) 0.19 1.0 (1.0–1.1) 0.29 1.1 (1.0–1.2) 0.15
BATF rs2300603 20.05 (20.2 to 0.05) 0.31 1.0 (0.9–1.0) 0.34 1.0 (0.9–1.1) 0.79
GALC rs2119704 20.01 (20.2 to 0.2) 0.93 1.0 (0.9–1.2) 0.77 0.9 (0.7–1.1) 0.44
16 CLEC16A rs7200786 0.02 (20.06 to 0.1) 0.59 1.0 (1.0–1.1) 0.67 1.1 (1.0–1.2) 0.28
IRF8 rs13333054 0.1 (20.01 to 0.2) 0.07 1.1 (1.0–1.2) 0.05 1.1 (1.0–1.3) 0.09
Continued
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shown to develop milder disease, with decreased
demyelination and reduced recruitment of inflamma-
tory cells to the brain.36 Evidence for multiple linked
quantitative trait loci within the Tmevd2/Eae interval
controlling disease severity in mice has also been re-
ported.37 However, these findings have not been rep-
licated in humans.
The present study had many strengths. First, the
MSSS has been favored over EDSS to capture dis-
ease severity in MS because it incorporates disease
duration to account for time.21 This approach builds
on earlier work38 and is advantageous for large stud-
ies where EDSS measurements may have only been
recorded at a single time point. We used data from
a large, independent cohort reference (Global
MSSS) to assign MSSS for each case in the present
study. Sparse data were therefore avoided for cells in
the reference table and potentially much larger var-
iances, and missing data, in general; both could
result from small sample sizes if our cohorts, which
vary greatly in size, had been characterized instead
by local MSSS.21 Furthermore, the large sample size
used to create the Global MSSS made it possible to
reduce the effect of stochastic fluctuations over time.
Specifically, EDSS scores in the surrounding 2 years
for each disease duration year are accounted for in
the ranking; very large data sets are required to do
this. It is important to note that the Global MSSS
reference data set is at least ;5 times larger than the
largest individual cohort in the present study. The
power of Global MSSS for genetic studies based on
the large pooled reference data has also been previously
demonstrated.21
Additional strengths included application of a sta-
tistical model for association testing that accounted
for random (cohort) effects, and we adjusted for
potential confounders such as age and sex. More-
over, use of MSSS extremes analysis reduced the
possibility of phenotype misclassification because in-
dividuals with benign disease were compared with
individuals with severe disease, and individuals in
the middle of the MSSS spectrum who are most
likely to be misclassified were excluded. While re-
stricting analyses to extreme categories of MSSS
reduced the overall number of individuals in our
data set, given our overall large sample size, close
to 4,000 individuals were still available for associa-
tion testing.
Analyses were also restricted to individuals with 10
or more years of disease duration since symptom
onset, to help ensure stability of the MSSS. At least
1 year of duration is required before the EDSS can
be used to calculate the MSSS with the published
algorithm.21 Median time to requiring unilateral assis-
tance ranges from 15 to 30 years in MS, based on the
present estimates.24 Conservatively, the present study
used disease duration near the median value for the
overall data set (table 1), but before the early end of
the transition to requiring unilateral assistance (or an
EDSS of 6). When analyses were restricted by disease
duration ($5, $10, $15, and $20 years), wGRS,
GRS, and individuals SNPs (data not shown) were
Table 3 Continued
Chr Gene SNP
MSSS outcome
Continuous Binary Extremea
b (95% CI)b p Value OR (95% CI)b p Value OR (95% CI)b p Value
17 STAT3 rs9891119 20.02 (20.1 to 0.07) 0.63 1.0 (0.9–1.1) 0.93 1.0 (0.9–1.1) 0.95
18 MALT1 rs7238078 20.06 (20.2 to 0.04) 0.24 1.0 (0.9–1.0) 0.27 1.0 (0.8–1.1) 0.44
19 TNFSF14 rs1077667 20.04 (20.2 to 0.07) 0.47 1.0 (0.9–1.0) 0.28 1.0 (0.9–1.2) 0.98
TYK2 rs8112449 20.01 (20.1 to 0.09) 0.85 1.0 (0.9–1.1) 0.53 0.9 (0.8–1.0) 0.20
MPV17L2 rs874628 0.1 (0.02 to 0.2) 0.02 1.1 (1.0–1.2) 0.03 1.2 (1.0–1.3) 0.01
DKKL1 rs2303759 0.06 (20.04 to 0.2) 0.24 1.1 (1.0–1.2) 0.05 1.0 (0.9–1.2) 0.51
20 CD40 rs2425752 0.03 (20.1 to 0.06) 0.52 1.0 (0.9–1.0) 0.27 1.0 (0.9–1.1) 0.58
CYP24A1 rs2248359 0.07 (20.02 to 0.2) 0.13 1.1 (1.0–1.1) 0.20 1.1 (0.9–1.2) 0.39
22 MAPK1 rs2283792 0.06 (20.03 to 0.1) 0.19 1.0 (1.0–1.1) 0.28 1.1 (1.0–1.2) 0.18
SCO2 rs140522 20.02 (20.1 to 0.08) 0.71 1.0 (0.9–1.1) 0.99 1.1 (0.9–1.2) 0.36
Abbreviations: CI 5 confidence interval; MS 5 multiple sclerosis; MSSS 5 Multiple Sclerosis Severity Score; OR 5 odds
ratio; SNP 5 single nucleotide polymorphism.
These marginal models tested the association between the 3 MSSS phenotypes and all 52 individual SNPs. Cohort was
a random-effect variable in the models.
aA total of 3,795 individuals with MS are included in this analysis.
bAll bs and ORs are from the adjusted models. Models are adjusted for sex, age at onset, HLA-DRB1*15:01, and cohort.
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not associated with any of the 3 MSSS outcomes
(figures e-4 and e-5).
There were also several limitations in this study.
The EDSS used to calculate the MSSS is heavily
weighted by physical measurements of disability.
While MSSS is a widely accepted measure of disabil-
ity for MS research, there are concerns about its sen-
sitivity, given that different combinations of disease
duration and EDSS can result in similar measures
of the MSSS. In addition, it is possible that
population-specific EDSS rankings could differ from
those derived using the Global MSSS. A genetic asso-
ciation might therefore only be uncovered when
a population is examined independently. Even larger
studies will be required to determine whether studies
of disability based on locally derived values for MSSS
reveal population-specific genetic effects. Further-
more, because subclinical disease can occur many
years before clinical symptom onset, the measure of
disease duration required to derive the MSSS may
not be accurate. Recent work shows that age could
potentially be used for ranking EDSS in future studies
when disease duration is unknown, because the exact
age of symptom onset may not be certain.39 Longitu-
dinal data on progression were not available for cases
in the present study. There is also potential selection
bias if individuals with mild disease are more willing
to participate in research studies than those with
severe disease. However, more than 1,100 partici-
pants were categorized in the highest or “most severe”
MSSS phenotype in the present study (table 1),
which provided a sufficient representation of cases
with severe disease. Finally, our negative findings
may have resulted from population or individual fac-
tors that could be not assessed in the present study.
Additional genetic variants (untested), environmental
exposures, or medication histories were not available
and may distinguish MSSS differences in the presence
or absence of the established genetic risk variants that
were investigated.
The current data set includes 52 non-MHC MS
genetic risk variants,10 and a larger list of the most
recently identified non-MHC MS risk variants
through GWAS and follow-up studies is now avail-
able.11 The 52 non-MHC MS risk variants used here
were stronger genetic markers of MS susceptibility;
the average OR based on GWAS for our 52 non-
MHC variants is 1.19 vs average OR for new 48
non-MHC variants, which is 1.09.10,11 GWAS of dis-
ease severity, to date, have not yet yielded new can-
didates at genome-wide significance5,10; and while
disease risk and severity variants appear to differ in
MS, this still remains a question. We have compre-
hensively pursued testing of the strongest established
disease risk variants identified, thus far, for evidence
of influence on MS severity. Larger studies of cases
with additional genotype data for newly discovered
GWAS variants are warranted. Finally, whole-
genome data were not available to formally adjust
for potential effects of population stratification. How-
ever, this was not a case-control study, each cohort
was treated separately in the analysis, and consistent
nonsignificant estimates for each of the 10 indepen-
dent cohorts were observed. Our findings in this
large, well-powered study are unlikely to result from
population stratification.
Results derived from investigation of a large
number of recently established GWAS variants in
7,125 MS cases suggest that the genetics underly-
ing MS susceptibility and disease severity, as mea-
sured by MSSS, do not substantially overlap.
Sensitive measures of severity and progression are
needed, and for larger prospective cohort studies
of incident cases. Comprehensive quantitative trait
data derived from high-resolution brain MRIs can
be used as dependent variables for a GWAS, as
recently demonstrated with 284 MS patients,40 or
for whole-genome sequencing studies. Longitudi-
nal studies will be informative for genetic investi-
gations. However, such studies will be necessarily
balanced by a lack of statistical power to detect
modest genetic effects unless very large numbers
of individuals can be assembled and followed for
long periods of time.
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